Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA Technologies, Inc. (SIGA) has received an increase in funding of approximately $23 million from the United States Department of Defense (DoD) to support research for expanding the FDA label of its antiviral drug TPOXX (tecovirimat) for Post-Exposure Prophylaxis (PEP) against smallpox. This potential label expansion is crucial in the event of a smallpox outbreak, as vaccines alone have limitations in effectiveness. TPOXX may be administered over 28 days for PEP, contrasting with the 14-day treatment for active infections. The company aims to enhance early treatment options for individuals at risk.
On June 1, 2020, SIGA Technologies, Inc. (SIGA) announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 16, 2020, at 10:30 a.m. Eastern Time, due to COVID-19 safety concerns. Stockholders as of April 24, 2020, can attend the meeting via a live audio webcast. They must submit their votes in advance, as voting during the meeting will not be permitted. SIGA focuses on health security and is known for TPOXX, a treatment for smallpox. A notice regarding the virtual format has been filed with the SEC.
SIGA Technologies announced the delivery of 2,500 courses of TPOXX® (tecovirimat) to the Canadian Department of National Defence as part of an agreement for up to 15,325 courses valued at $14.3 million. Deliveries are expected to continue pending regulatory approval by Health Canada. Additionally, SIGA plans to deliver $101.3 million of TPOXX to the U.S. Government related to a BARDA contract. The contract could yield up to $414 million in future purchases, underscoring SIGA's role in biodefense and health security.
SIGA Technologies, Inc. (SIGA) reported a Q1 2020 revenue of approximately $2.6 million, resulting in an operating loss of about $4.0 million and a loss per diluted share of $0.11. The company exercised contract options totaling $101.3 million from BARDA for oral TPOXX® deliveries expected by April 2021. SIGA also maintains a strong cash position of $77.4 million. Despite concerns over the COVID-19 pandemic, the company does not anticipate a material adverse effect on its financial condition or annual results.
Summary not available.
Summary not available.